Get the Daily Brief
Latest Biotech News
Corxel bags $287M to advance oral GLP‑1 CX11
Corxel Pharmaceuticals closed a $287 million Series D1 round to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist for obesity and type 2 diabetes. Investors...
China’s gene and cell therapy push: New rules and durable early‑stage edge
BioCentury reported Chinese regulators introduced rules permitting medical centers to charge for investigational gene and cell therapies, a shift that creates incentives for hospitals to deploy...
Fortitude Biomedicines launches: GLUE‑DAC ADCs target resistance
Fortitude Biomedicines launched with $13 million in seed funding to develop antibody‑drug conjugates carrying targeted protein degraders (GLUE‑DAC), aiming to overcome ADC resistance and expand...
Sarepta’s Elevidys: Three‑year durability amid safety scrutiny
Sarepta released three‑year follow‑up data for Elevidys (delandistrogene moxeparvovec) showing durable efficacy across motor function assessments versus external controls, with the gap widening...
AI-designed anti-CRISPRs: rapid off-switch proteins for Cas13
Researchers at Monash University and the University of Melbourne reported the de novo design of artificial anti-CRISPR proteins that inhibit Cas13a and validated activity in bacterial and human...
Sarepta’s Elevidys: three-year data revives efficacy conversation
Sarepta Therapeutics released three‑year follow-up data from its pivotal DMD trial showing durable motor-function benefit for Elevidys (delandistrogene moxeparvovec) versus historical controls,...
Worldwide Clinical Trials buys Catalyst to bulk up early‑phase oncology
Kohlberg‑backed CRO Worldwide Clinical Trials agreed to acquire UK‑based Catalyst Clinical Research to expand early‑phase oncology capabilities and add functional service provider (FSP) offerings....
Eclipsebio acquires Terrain Bio to build end‑to‑end RNA platform
RNA genomics firm Eclipsebio acquired Terrain Bio to integrate machine‑learning RNA analytics into a sequencing‑first platform for RNA therapeutic design and manufacturing. Eclipsebio said the...
10x Genomics pivots to clinical: CLIA lab and analysis partnerships
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana-Farber Cancer Institute, and the Cancer Research Institute while committing to build a CLIA‑certified lab...
Epidarex Capital raises $145M to back next‑gen UK‑US life science startups
Life‑science investor Epidarex Capital closed a $145 million first close on its fourth fund to target overlooked UK and US research corridors and seed the next generation of platform and...
Cultivated‑meat startup Innocent Meat raises €6M to build demo production
German cultivated‑meat startup Innocent Meat secured €6 million to develop a fully automated, software‑driven production system and to build a demonstration facility aimed at traditional meat...
FDA approvals: 27 in December brings 2025 total to 226
The U.S. Food and Drug Administration approved 27 drugs in December 2025—the month’s high—bringing the annual total to 226 approvals. That places 2025 just below 2024’s 228 approvals but well...
Industry sues IRA drug pricing: petitions reach Supreme Court
Novartis became the sixth drugmaker to bring a legal challenge to the U.S. Supreme Court over the Inflation Reduction Act’s drug pricing provisions, escalating a multi‑year industry battle over...
Parse and Graph partner to build massive functional immune perturbation atlas
Parse Biosciences and Graph Therapeutics announced a strategic partnership to generate a large, multi‑context immune perturbation atlas by profiling hundreds of millions of cells from patients...
FDA draft nudges biosimilars away from efficacy trials – industry splits
The US Food and Drug Administration issued draft guidance recommending comparative analytical assessments (CAAs) as the primary route to demonstrate biosimilarity, advising that comparative...
AI designs anti‑CRISPRs: rapid Cas13 inhibitors emerge in eight weeks
Researchers at Monash University and the University of Melbourne reported de novo, AI‑designed anti‑CRISPR proteins (AIcrs) that inhibit Cas13a, validating hits in bacterial and human cells and...
10x Genomics pivots to clinic – CLIA lab build and hospital deals announced
10x Genomics signaled a strategic move beyond research tools by announcing clinical collaborations with Brigham & Women's Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute,...
Eclipsebio buys Terrain Bio – stacks AI RNA design with sequencing analytics
Eclipsebio acquired Terrain Bio to accelerate an end‑to‑end platform that spans AI‑driven RNA design through manufacturing and high‑resolution sequencing validation. Eclipsebio said Terrain’s...
Worldwide Clinical Trials buys Catalyst – early‑phase oncology push via FSP
Worldwide Clinical Trials agreed to acquire UK‑based Catalyst Clinical Research to strengthen early‑phase oncology capabilities and add a functional service provider (FSP) model to its offerings....
Sarepta: three‑year Elevidys data claim growing efficacy despite prior safety and sales headwinds
Sarepta released three‑year follow‑up data for its Duchenne gene therapy Elevidys, reporting durable benefits on motor function measures versus historical controls and an expanding gap between...